Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through entities he is associated with, under a pre-arranged trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock indirectly through Forbion Capital Fund IV Cooperatief U.A. (FCF IV) and ForDyne B.V.
• The sales occurred on August 28 and 29, 2024.
• A total of 134,261 shares were sold across multiple transactions at weighted average prices ranging from $44.41 to $45.81.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by FCF IV on April 9, 2024.
• Kersten disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
• After the reported transactions, FCF IV directly holds 549,175 shares and 487,708 shares, 442,068 shares and 431,300 shares.
• ForDyne B.V. directly holds 5,795,364 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports stock sales under a pre-arranged trading plan, which doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider selling can sometimes be interpreted negatively by the market, but the existence of a pre-arranged trading plan mitigates this concern as it indicates the sales were planned in advance and not based on current, non-public information.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan may alleviate concerns.

Key Dates